MedTrace Logo

Metronomic Capecitabine in Stage III Gastric Cancer

NCT06313567 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 722

Last updated 2024-07-08

No results posted yet for this study

Summary

The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment.

Conditions

Interventions

DRUG

Metronomic capecitabine group

500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group

OTHER

Observation

observation

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-10
Primary Completion
2029-03-10
Completion
2029-03-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06313567 on ClinicalTrials.gov